initial diagnosis (Kirby, Hirst, & Crawford, 2011) . Historically, few treatment options were available to men with mCRPC and this advanced disease was considered to confer a terminal prognosis with a median survival of 7-15 months from development of castration resistance (National Institute for Health & Clinical Excellence, 2009 ).
The emergence of therapies suppressing androgen signalling has changed the treatment paradigm and prognosis for men with mCRPC (Gupta, Guthrie, & Tan, 2014; Suzman & Eisenberger, 2014) . Abiraterone acetate is a selective inhibitor of CYP17, the key enzyme in androgen synthesis. In 2011, abiraterone acetate in combination with low dose prednisone (a synthetic corticosteroid), was the first non-cytotoxic therapy to be approved by the (Gartrell & Saad, 2015; Saad, 2013) .
Life-prolonging treatments for cancer should seek not only to enable patients to live longer but also to enable patients to live as near normal a life as possible. This entails measuring not only the length of survival but also the quality of this survival in terms of patients' experience of symptoms, adverse events and HealthRelated Quality of Life (HRQoL). Randomised controlled trials alone are not sufficient for evaluating such outcomes and evidence from real-world studies for new therapies is necessary to supplement that derived from clinical trials. To date, there is little-published evidence regarding patients' real-world experience of either AAP or ENZ, particularly in terms of prominent symptoms/side effects of treatment, treatment satisfaction and HRQoL (Sanda et al., 2008) .
Cancer-related fatigue is the most common and distressing symptom for patients with mCRPC and is also a commonly reported adverse event associated with treatment (Colloca, Venturino, Governato, & Checcaglini, 2016; Stone & Minton, 2008) . Furthermore, there is some evidence linking patient satisfaction and HRQoL to adherence to treatment (Barbosa, Balp, Kulich, Germain, & Rofail, 2012) which is critical for maximising the likelihood of successful outcomes of therapy (Bosnjak, Radulovic, Neskovic-Konstantinovic, & Mitrovic, 2000; Foulon, Schöffski, & Wolter, 2011) .
The overall objective of the current study was to better understand and quantify the experience of living with mCRPC in patients receiving AAP or ENZ in either pre-chemotherapy or post-chemotherapy settings. Any emerging differences between patients receiving AAP and ENZ were explored.
| ME THODS
This study utilised a combination of qualitative and quantitative research methods. Informed consent was obtained from all patients for each phase of the study and ethical approval was granted by Freiburger Ethik-Kommission International (study code: 22500, FEKI code 014/1826).
| Qualitative interviews with mCRPC patients
Clinicians in each country (France, Germany and the UK) identified eligible patients currently receiving AAP or ENZ and who had been on treatment for a minimum of two months.
As a first-step, qualitative face-to-face interviews were conducted with mCRPC patients (n = 38) and their carers (n = 12) to elicit in-depth insights concerning the patient and carer experience of therapy with AAP or ENZ in the pre-chemotherapy (AAP = 11, ENZ = 9) or post-chemotherapy settings (AAP = 7, ENZ = 11). All interviews were approximately 60 minutes in length and were conducted by trained interviewers in local language using a semi-structured interview guide. All interviewers were specialists in qualitative research with extensive experience of moderating interviews with patients that focus on health-related issues. All interviewers were fully briefed about the study and received detailed study-specific training via web conference prior to conducting the interviews. Interviews were conducted with patients in France (n = 14), Germany (n = 14) and the UK (n = 10). Prior to the interview, patients completed a 7-day diary to record their experiences and the diary was used as a discussion aid during the interview.
Patients were asked to draw out the highs and lows of their treatment journey, from the commencement of treatment until the point of the interview, on a blank graph. Patients were free to define high and low points in their own way and the graphical drawing was used to elicit discussion between the patient and the interviewer.
Important concepts related to the patient experience of androgen suppressing drugs were identified using thematic analysis (Braun & Clarke, 2006) . Findings from these qualitative interviews were used to inform the selection of patient-reported outcome (PRO) measures to be implemented in the larger quantitative survey of men with mCRPC on these two agents.
| Quantitative survey
A total of 152 men from France (n = 54), Germany (n = 81) and the UK (n = 17) with mCRPC and currently receiving AAP or ENZ either in a pre-chemotherapy (AAP = 49, ENZ = 38) or post-chemotherapy (AAP = 29 and ENZ = 36) setting were recruited to participate in a quantitative survey. Similar to the qualitative phase, patients were identified via clinicians; eligible patients had to have been receiving AAP or ENZ treatment for a minimum of two months.
Eligible patients were provided with a link to an online self-administered survey. Those patients unable to access the Internet were provided with the option of paper questionnaires posted to them for completion and return. Patients were informed that the survey would take them approximately 30 minutes to complete and were asked to complete the survey at home.
At the start of the survey, patients were asked to provide some demographic and clinical information which would be used to help characterise and describe the sample. Patients were then asked to complete the following PRO questionnaires:
• The Brief Fatigue Inventory (BFI): The BFI comprises nine items used to assess the severity and impact of cancer-related fatigue.
All items are rated on a scale from 0 (no fatigue/does not interfere) to 10 (fatigue as bad as you can imagine/completely interferes).
Eight of the nine items use a recall period of the "past 24-hours" and one item assesses fatigue "right now". A global fatigue score can be calculated as an average of all item responses (Shahid, Wilkinson, Marcu, & Shapiro, 2012) .
• Cancer Therapy Satisfaction Questionnaire (CTSQ): The CTSQ is a patient-completed questionnaire developed and validated for use in a number of cancers which can be used with intravenous and/ or oral chemotherapy, biological and hormonal therapies (Trask, Tellefsen, Espindle, Getter, & Hsu, 2008) . The CTSQ comprises 16-items measuring three domains; expectations of therapy (ET), feelings about side effects (FSE) and satisfaction with therapy (SWT). Each domain is scored from 0 to 100 with higher scores representing greater satisfaction (Trask et al., 2008) Age, n (%) ≤65 years 13 (34) 34 (22) 18 (23) 16 (22) 66-75 years 15 (40) 65 (43) 35 (45) 30 (40) ≥76 years 10 (26) 49 (32) 23 (29) 26 (35) Did not want to answer 0
Work status, n (%)
Working full time/part time/self employed 0 23 (15) 16 (20) 7 (9) Retired/not working 38 (100) 127 (84) 62 (80) 65 (88) Other
2014 -35 (23) 18 (23) 17 (23) 2015 -105 (69) 56 (72) 49 (66) No answer
Supported by a carer, n (%)
No support from carer N/A 95 (63) 52 (67) 43 (58) Support from spouse 10 (84) 37 (24) 19 (24) 18 (24) Support from other relative 1 (8) 11 (7) 4 (5) 7 (10) Support from friend/ neighbour
Use of previous treatment, n (%)
(24)
19 (24) 18 (24) Lupron/Trenantone/ Eligard/Prostap (Leuprorelin) -26 (17) 19 (24) 7 (9) Zoladex (Goserelin) -17 (11) 12 (15) 5 (7) Taxotere -15 (10) 10 (13) 5 (7) debriefing interviews were conducted with 12 mCRPC patients (currently receiving AAP or ENZ) to explore the content validity (i.e. relevance and understanding of items) of this instrument in this population.
• EuroQol-5-Dimensions 5-Levels (EQ-5D-5L): The EQ-5D-5L is a standardised instrument applicable to a wide range of health conditions and treatments, and requires respondents to rate their health status in terms of "Mobility", "Self-Care", "Usual Activities", "Pain/Discomfort" and "Anxiety/Depression" on a five-point response continuum (1-5) with lower scores representing better health. A "utility index score" can be calculated for each patient ranging from −0.59 to 1.00 with 1.00 indicating "full health". In addition, respondents rate their health status on 100 mm visual analogue scale (Rabin & Charro, 2001) .
The data from all 152 patients were entered into a database for analysis. The database was developed with quality control functionalities in place (e.g. validation alerts when out-of-range values are entered, auto-tabbing, spell checking, shortcut keys, data entry status flags). The patient scores per item and total scores for each questionnaire were calculated and stratified by therapy (AAP or ENZ) and treatment setting (pre-or post-chemotherapy). Statistical significance of group differences was explored using chi-square tests (when based on categorical data) and t tests (when based on ordinal/interval data).
| RE SULTS

| Qualitative interviews
Demographic and clinical characteristics of mCRPC patients participating in the qualitative interviews are provided in Table 1 . The 12 carers were all the main carers of patients enrolled in the study and four cares were recruited per country (France, Germany and the UK). Ten carers (83.3%) were the spouse/partner of the patient, one carer was the daughter of a patient (8.3%) and one carer (8.3%) was a paid carer.
Fatigue was reported by patients and carers in both the pre-chemotherapy and post-chemotherapy settings as a symptom which contributed to a "bad day" by impacting patients' ability to complete daily activities and reducing quality of life. Some patients and carers highlighted fatigue as a side effect of treatment and highlighted the impact of fatigue on patients' ability to concentrate.
When discussing their current treatment, it was clear that patients and carers expected treatments to deliver across a number of domains; reductions in prostate-specific antigen (PSA) levels, improvements in HRQoL (including reduction in side effects and maintaining general well-being) and maximising survival were all of primary concern, irrespective of current treatment. For both treatments, patients and carers reported that experiences had met or exceeded expectations in terms of treatment effectiveness and experience of side effects. Participants on both treatments also cited ease of administration as a key benefit of their current treatment. Analysis of the treatment journey drawing task found that the overall experiences and level of satisfaction appear to be similar between patients and carers for both treatments. who also completed the EQ-5D pain/discomfort item reported experiencing slight, moderate or severe pain or discomfort.
Anxiety and depression were discussed by some patients during the qualitative interviews and 15/37 (40.5%) of the patients who completed the EQ-5D anxiety/depression item reported feeling slightly, moderately or severely anxious or depressed. Negative experiences appeared to be associated with fluctuations in PSA levels and patients reported how these fluctuations negatively
impacted on their quality of life. Specifically, patients and carers
worried that a rise in PSA levels was a sign that the treatment was 
| Quantitative survey
Demographic and clinical characteristics of mCRPC patients participating in the quantitative survey are provided in Table 1 . This sample In both treatment groups, over 70% of patients were over 66 years of age and over 78% of the sample was retired. Despite the age of the patients, the majority of patients in both treatment groups were not supported by a carer and those that were supported were most frequently supported by a spouse. The majority of patients started their current treatment in 2015, and the longest a patient had been taking a treatment was since 2011. A total of 97 patients completed the survey online and 55 patients completed the paper version (Table 1) .
| Fatigue
A mean BFI score of 3.2, indicative of mild to moderate fatigue was reported in the total sample (n = 152). Patients in the AAP group reported lower fatigue scores (mean = 2.9, n = 78) than patients in the Comparisons of BFI scores by treatment setting (e.g. pre-chemotherapy and post-chemotherapy) reveal a trend towards lower scores in patients in the pre-chemotherapy setting compared to those in the post-chemotherapy setting. BFI scores in the AAP group were lower than those in the ENZ group regardless of the treatment setting (pre-chemotherapy or post-chemotherapy).
| Satisfaction with cancer therapy
Feedback from mCRPC patients participating in cognitive interviews supported the content validity of the CTSQ, with participants demonstrating consistent understanding of CTSQ items. No important concepts were identified by participants as missing from the CTSQ.
Participants also reported finding completion of the CTSQ online to be "easy" and "straightforward".
Scores for all patients were highest for the CTSQ domain of satisfaction with therapy, followed by feelings about side effects; with patients being least satisfied with treatment according to the expectations of therapy domain (Table 2 ). That scores were lowest for the expectations of therapy domain of the CTSQ is consistent with feedback during the cognitive interviews that, as a result of cancer metastasising, participants would not expect treatment to help them "return to normal life" (item one), "get rid of the cancer" (item two), "prevent the cancer from coming back" (item three) and "stop the cancer from spreading" (item four).
Cancer Therapy Satisfaction Questionnaire domain scores were similar for patients receiving AAP and patients receiving ENZ, in both the pre-chemotherapy and post-chemotherapy settings (Table 2) .
Patients receiving treatment in the pre-chemotherapy setting were generally more satisfied with their treatment than those receiving treatment in a post-chemotherapy setting; however, these differences were not statistically significant (p = 0.355-0.877).
| Health status
Mean EQ-5D-5L Utility Index and VAS scores were high across all patient groups, indicating good overall self-reported health When data were compared within AAP and ENZ treatment groups, no statistically significant differences were observed between those patients treated in a pre-chemotherapy versus postchemotherapy setting. Of note, higher EQ-5D utility scores and ratings of health status were observed among patients in the AAP pre-chemotherapy setting compared to patients in the AAP postchemotherapy setting; however, these differences were not statistically significant (utility score: p = 0.070 and health status: p = 0.056;
Figures 3 and 4).
| D ISCUSS I ON
Since the approval of AAP and ENZ, outcomes among mCRPC pa- Beer et al., 2014; Cabot et al., 2012) . However, to date, there has been a limited exploration of experiences of fatigue and associated impact among patients receiving these therapies in a real-world setting. During qualitative interviews conducted as part of this study, fatigue was commonly associated with a "bad day".
The results of the quantitative survey suggest that whilst patients receiving both therapies report experiencing fatigue, levels of selfreported fatigue and fatigue-related impairment among patients receiving AAP were less than patients receiving ENZ.
Abiraterone acetate and enzalutamide are both oral therapies In this particular study, for example, mean utility values generated using the UK specific EQ-5D were 0.66 (Diels et al., 2015) .
| Study limitations
To account for any regional and cultural differences, participants in the current study were recruited from three different EU countries (France, Germany and the UK). However, it should be acknowledged that there were notable differences in the number of patients recruited from each country; the UK sample in particular is comparatively small (n = 17) when compared to the number of participants recruited from France (n = 54) and Germany (n = 81). The reduced UK sample was not by design but rather a result of challenges encountered in the identification and recruitment of eligible participants in the UK. For context, in the UK at the time of the study, physicians had to apply for specific funding to prescribe AAP and ENZ. It should also be acknowledged that more complex medical information relating to dosing, dose reductions and PSA levels was not collected, due to a concern that patients would not be able to accurately recall this information. In future studies, clinicians may be asked to provide this information to further describe the clinical characteristics of the patient populations and explore how these factors can impact on HRQoL.
The sample was restricted to patients receiving AAP and ENZ in pre-chemotherapy and post-chemotherapy settings. Both treatments suppress androgen receptor signalling, however, other new agents have also demonstrated survival benefits in mCRPC, including radium-223 dichloride, sipuleucel-T and cabazitaxel (Omlin, Pezaro, & Sommer, 2014) . It is important to acknowledge that the results of this study may not necessarily be generalisable to the overall mCRPC population and patients receiving other therapies.
Finally, this was a cross-sectional study designed to provide an understanding of the patient experience of fatigue, treatment satisfaction and HRQoL. As patients were only assessed at a single time-point, it is not possible to know whether observed treatment differences are a reflection of differences in patient's experiences of AAP versus ENZ, or reflect pre-treatment differences in these patients. Future research may look to measure outcomes prospectively to assess long-term outcomes and any change over time. It is particularly important to assess whether the outcomes reported by patients can be sustained over the full disease pathway.
| CON CLUS ION
Findings from the current study provide insight into the patient experience of therapies suppressing androgen signalling for the treatment of mCRPC. Patients in both treatment groups were largely satisfied with their treatment and reported high levels of health status and quality of life. This serves to highlight the benefit of these treatments in not only improving survival but also
promoting the "quality" of the survival period. Self-reported fatigue severity and fatigue-related impairment were significantly lower in patients receiving AAP than patients receiving ENZ and this may be important for informing individual treatment decisions. Future longitudinal and prospective research is needed to assess fatigue, treatment satisfaction, HRQoL and other symptoms/adverse events throughout the period of survival on these therapies.
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